Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Chronopharmacokinetics: Time-Dependent Pharmacokinetics01:20

Chronopharmacokinetics: Time-Dependent Pharmacokinetics

Chronopharmacokinetics studies the temporal change in drug absorption and elimination. These changes can be cyclical or non-cyclical. Cyclical changes occur over a regular interval, while non-cyclical changes occur over a longer, irregular period.
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutagenesis of bracelet cyclotide hyen D reveals functionally and structurally critical residues for membrane binding and cytotoxicity.

The Journal of biological chemistry·2022
Same author

Cystine Knot Peptides with Tuneable Activity and Mechanism.

Angewandte Chemie (International ed. in English)·2022
Same author

Protocols for measuring the stability and cytotoxicity of cyclotides.

Methods in enzymology·2022
Same author

Phage display-based discovery of cyclic peptides against the broad spectrum bacterial anti-virulence target CsrA.

European journal of medicinal chemistry·2022
Same author

Towards a generic prototyping approach for therapeutically-relevant peptides and proteins in a cell-free translation system.

Nature communications·2022
Same author

Enzymatic C-to-C Protein Ligation.

Angewandte Chemie (International ed. in English)·2022
Same journal

AKR1C3 inhibitors and exploiters for the treatment and therapeutic monitoring of cancer: a patent review 2020-present.

Expert opinion on therapeutic patents·2026
Same journal

An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020-present).

Expert opinion on therapeutic patents·2026
Same journal

Takeda G-protein-coupled receptor 5 and farnesoid X receptor agonists for diabetes treatment: a patent review and clinical advancements (2015-present).

Expert opinion on therapeutic patents·2026
Same journal

A patent review of GPR84 receptor antagonists (2020-present).

Expert opinion on therapeutic patents·2026
Same journal

SLIT2 and ROBO-Axis inhibitors for the treatment of cancer: a patent review (2020-2026).

Expert opinion on therapeutic patents·2026
Same journal

New insights on anticancer glucocorticoid receptor modulators: a patent review (2020-present).

Expert opinion on therapeutic patents·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

Cyclotides: a patent review.

Amanda B Smith1, Norelle L Daly, David J Craik

  • 1Intellectual Property & Development, The University of Queensland, IMBcom Pty Ltd, Brisbane, Australia.

Expert Opinion on Therapeutic Patents
|October 25, 2011
PubMed
Summary
This summary is machine-generated.

Cyclotides, stable cyclic peptides from plants, show promise as scaffolds for drug design. Their unique structure allows grafting of bioactive sequences, creating robust peptide-based therapeutics with potential applications in medicine and agriculture.

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Constructing Cyclic Peptides Using an On-Tether Sulfonium Center
07:11

Constructing Cyclic Peptides Using an On-Tether Sulfonium Center

Published on: September 28, 2022

Related Experiment Videos

Last Updated: May 28, 2026

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
08:48

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation

Published on: January 26, 2016

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Constructing Cyclic Peptides Using an On-Tether Sulfonium Center
07:11

Constructing Cyclic Peptides Using an On-Tether Sulfonium Center

Published on: September 28, 2022

Area of Science:

  • Biochemistry
  • Medicinal Chemistry
  • Peptide Science

Background:

  • Cyclotides are plant-derived mini-proteins characterized by a cyclic backbone and a cystine knot, conferring exceptional stability.
  • Their natural roles include insecticidal activity, while pharmaceutical potential spans anti-HIV, antimicrobial, and uterotonic effects.
  • Both natural biosynthesis and synthetic methods (solid-phase peptide synthesis, recombinant) are established for cyclotide production.

Purpose of the Study:

  • To review patent literature concerning cyclotides and their therapeutic applications.
  • To highlight the use of cyclotide cystine knot scaffolds in developing peptide-based drug leads, molecular probes, and diagnostic agents.

Main Methods:

  • Review of patent literature focused on cyclotide applications.
  • Analysis of patents related to cystine knot scaffolds for therapeutic development.

Main Results:

  • Patents demonstrate the feasibility of using cyclotide scaffolds for drug development.
  • Proof-of-concept exists for grafting bioactive peptide sequences onto cyclotide frameworks.
  • Grafted sequences maintain biological activity and gain resistance to proteolysis.

Conclusions:

  • Cyclotides represent promising templates for peptide-based drug development due to their stability and synthetic accessibility.
  • Further interest is growing in cyclotides and related disulfide-rich scaffolds for medicinal chemistry applications.
  • While no cyclotide-based drug has reached clinical trials, their potential as stable therapeutic scaffolds is significant.